The amyloidogenic and non-amyloidogenic cleavages of APP are the basis for detecting of the cerebrospinal fluid (CSF) βA marker which, together with total tau (t-tau) and phosphorylated tau (p-tau), as well as neuroimaging analyses, are considered gold standards to identify the underlying pathophysiology at the earliest stages of AD. This evidence concerns the gene MAPT and Alzheimer disease.